Skip to content

Viscoelasticity Imaging to Assess Liver Cancer

Liver Cancer

Ultrasound (US) used for hepatocellular carcinoma (HCC) surveillance suffers from low sensitivity (60-78%) due to fatty liver, obesity, and diffusely nodular appearance in cirrhosis. Once a suspicious malignant lesion is detected at US, guidelines recommend contrast-enhanced US, magnetic resonance imaging (MRI) or computed tomography (CT) scans to confirm suspicion. The investigators' team has developed innovative quantitative US (QUS) techniques that have a high potential to improve tissue characterization in terms of sensitivity and specificity. The investigators hypothesize that advanced QUS providing tumor viscoelasticity assessment, sub-resolution tissue structure characterization and US attenuation in the framework of a machine learning classification model can improve HCC diagnosis compared with standard US.

Early detection through systematic US surveillance translates into curative therapy in a higher proportion of patients and into improvements in survival rates. Thus, there is an urgent need to investigate innovative and cost-effective imaging techniques for improving detection and characterization of HCC. The proposed QUS methods are experimental and will be validated in this proof-of-concept clinical study. A major impact of this work, for patients and medical institutions, will be to improve early-stage detection and characterization of HCC, and offer alternatives in patients with negative or inconclusive conventional US. QUS are low-cost, non-invasive and non-irradiating imaging modalities available from a single exam (i.e., no additional imaging session is necessary).

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Are at least 18 years old at screening;
* Able to comprehend and willingness to provide voluntary consent;
* Are able to have a MRI;
* Understand French or English;
* Patients enrolled in a monitoring program or referred for the characterization of a focal liver lesion;
* Focal liver lesion is visible during ultrasound screening in B-mode.

Exclusion Criteria:

* Are pregnant or trying to become pregnant;
* Have a weight or girth preventing from entering the MR magnet bore;
* Are unable to understand or unwilling to provide written informed consent for this study;
* Have a contraindication to MRI (pacemaker, insurmountable claustrophobia);
* Have chronic kidney disease preventing the injection of gadolinium-based contrast agent.

Lieu de l'étude

Centre hospitalier de l'Université de Montréal (CHUM)
Centre hospitalier de l'Université de Montréal (CHUM)
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Backup Contact

Louise Allard, PhD

[email protected]
514-890-8000
Primary Contact

Guy Cloutier, PhD

[email protected]
514-890-8000
Étude parrainée par
Centre hospitalier de l'Université de Montréal (CHUM)
Participants recherchés
Plus d'informations
ID de l'étude: NCT04409340